GlassScriptPhysician profile
Ushma Shah
NPI 1467865295
$2,025.42
in general payments reported to CMS, 2019-2025
10 companies · $836 in 2025
The $836 reported for 2025 was more than what 76% of Infectious Disease providers received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $230 · 2020: $166 · 2021: $52.23 · 2023: $171 · 2024: $570 · 2025: $836.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,576.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,013.56 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $404.32 | 2019-2025 | Zerbaxa, Dificid, Pifeltro |
| Abbvie INC. | $202.24 | 2021-2024 | |
| Insmed, INC. | $113.20 | 2023 | |
| Aimmune Therapeutics, INC. | $92.89 | 2024 | |
| Astellas Pharma US INC | $77.80 | 2020 | |
| Allergan, INC. | $47.71 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Paratek Pharmaceuticals, INC. | $24.00 | 2019 | |
| Viiv Healthcare Company | $21.22 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ushma Shah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.